Epigenomics Enters Agreement with Biochain on Lung Cancer Test for China
March 30, 2016
Epigenomics AG :
* Enters strategic license and development agreement with Biochain on novel, blood-based lung cancer test for China
* Will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues
* Biochain will initiate a clinical trial to validate lung cancer detection test with goal to gain market approval by CFDA
* Trial is expected to start in 2016
Source text for Eikon: Further company coverage: (Gdynia Newsroom)
